4.9-Star Rating on Shopee and TikTok Shop Thailand | 16,000+ Verified Reviews

Key Highlights

• Ranked #1 in Sunscreen category on Amazon UK (*April 14, 2026)
•  A European favorite, certified under EU CPNP – one of the world’s strictest cosmetic standards
• 4.9-star rating on Shopee and TikTok Shop Thailand from 16,000+ verified reviews (*as of April 29, 2026)
• Lightweight, zero white cast, optimized for Thailand’s hot-humid climate
• Thai FDA Registration No. 10-2-6700013181

BANGKOK, May 4, 2026 /PRNewswire/ — COSRX, a leading Korean beauty brand, announced today that its Ultra-Light Invisible Sunscreen SPF50 PA++++ has secured the No.1 position in the Sunscreen category in the Amazon UK as of April 14, 2026. Beyond its top ranking, the product has generated strong demand as a European favorite, while reinforcing its market leadership in Thailand with a 4.9-star rating on Shopee and TikTok Shop Thailand from over 16,000 verified consumers.

What is CPNP and Why Does It Matter to Thai Consumers?

The Cosmetic Products Notification Portal (CPNP) is the European Union’s mandatory cosmetic product notification system, requiring rigorous safety assessment before market entry. It is widely regarded as one of the world’s strictest cosmetic regulatory frameworks.

Following the recent UV protection issue, Thai consumers have voiced growing skepticism about the actual UV protection efficacy of the sunscreens. COSRX addresses these concerns with a scientifically validated solution that has become a European favorite – conquering a region renowned for the highest global standards in sun protection.

Why is COSRX Sunscreen Ideal for Thailand’s Climate?

According to the Thai Meteorological Department, the average UV Index in Bangkok measures 11+ (Extreme) year-round, while major urban centers like Khon Kaen, Hat Yai, and Nakhon Ratchasima experience similarly intense UV exposure throughout the year.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is engineered for these conditions:

• Watery, lightweight texture that absorbs quickly without stickiness
• Aloe Vera and Witch Hazel soothe the skin
• Zero white cast – suitable for all skin tones
• Clinically proven cooling effect that instantly reduces skin heat and redness by 86.32%

Who Recommends COSRX in Thailand?

The product has been endorsed by Thailand’s most authoritative skincare voices:

• @ingck – Recognized for ingredient-focused skincare reviews and hands-on testing
• @eb.bahboh – A highly respected medical doctor and creator offering science-backed dermatological expertise

Both have confirmed the product’s efficacy, protection, and suitability for Thai skin after extensive personal use.

Consumers in Thailand can explore COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ and the broader COSRX suncare range through the brand’s official stores on TikTok Shop Thailand and Shopee Thailand. Purchasing through official channels helps ensure product authenticity and access to the latest brand information.

Experience the UK’s No. 1 and Europe’s favorite sunscreen choice and explore the full COSRX range at the Official TikTok Shop Thailand and Official Shopee. COSRX is also on TikTok + Shopee.

Frequently Asked Questions (FAQ)

Q1. What does EU CPNP registration mean?

A1. EU CPNP registration means the product has been notified through the European Union’s Cosmetic Products Notification Portal before being placed on the EU market. It is part of the EU’s regulatory framework for cosmetics.

Q2. What proof supports the product’s consumer popularity in Thailand?

A2. As of April 29, 2026, the product holds a 4.9-star rating across Shopee and TikTok Shop Thailand, with more than 16,000 verified reviews.

Q3. Why is COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ suitable for Thailand’s climate?

A3. It delivers uncompromising, heavy-duty UV defense (SPF50 PA++++) to combat Thailand’s intense sun, without sacrificing daily comfort. Even in hot and humid weather, its watery, lightweight texture absorbs quickly, feels breathable on the skin, and leaves absolutely no white cast.

Q4. Does this sunscreen leave a white cast?

A4. No. COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is designed to deliver an invisible finish without leaving a noticeable white cast on skin.

Q5. Is this product registered in Thailand?

A5. Yes. Thai FDA Registration No. 10-2-6700013181.

Q6. Where can consumers buy authentic COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ in Thailand?

A6. Authentic products are available through COSRX’s official stores on Shopee Thailand and TikTok Shop Thailand.

About COSRX

Rooted in science and driven by results, COSRX is a global beauty brand known for its high performance yet affordable formulations that target real skin concerns with minimal ingredients and maximum efficacy. Trusted by skincare lovers worldwide, COSRX delivers visible results through carefully selected actives in concentrated doses. Discover its award-winning lineup at retailers including COSRX.com, Shopee, TikTok Shop, Beautrium, Watsons and EVEANDBOY. Follow @cosrx.thailand on Instagram and @cosrx.th on TikTok for the latest product drops, tips, and trends.

4.9-Star Rating on Shopee and TikTok Shop Thailand | 16,000+ Verified Reviews

Key Highlights

• Ranked #1 in Sunscreen category on Amazon UK (*April 14, 2026)
•  A European favorite, certified under EU CPNP – one of the world’s strictest cosmetic standards
• 4.9-star rating on Shopee and TikTok Shop Thailand from 16,000+ verified reviews (*as of April 29, 2026)
• Lightweight, zero white cast, optimized for Thailand’s hot-humid climate
• Thai FDA Registration No. 10-2-6700013181

BANGKOK, May 4, 2026 /PRNewswire/ — COSRX, a leading Korean beauty brand, announced today that its Ultra-Light Invisible Sunscreen SPF50 PA++++ has secured the No.1 position in the Sunscreen category in the Amazon UK as of April 14, 2026. Beyond its top ranking, the product has generated strong demand as a European favorite, while reinforcing its market leadership in Thailand with a 4.9-star rating on Shopee and TikTok Shop Thailand from over 16,000 verified consumers.

What is CPNP and Why Does It Matter to Thai Consumers?

The Cosmetic Products Notification Portal (CPNP) is the European Union’s mandatory cosmetic product notification system, requiring rigorous safety assessment before market entry. It is widely regarded as one of the world’s strictest cosmetic regulatory frameworks.

Following the recent UV protection issue, Thai consumers have voiced growing skepticism about the actual UV protection efficacy of the sunscreens. COSRX addresses these concerns with a scientifically validated solution that has become a European favorite – conquering a region renowned for the highest global standards in sun protection.

Why is COSRX Sunscreen Ideal for Thailand’s Climate?

According to the Thai Meteorological Department, the average UV Index in Bangkok measures 11+ (Extreme) year-round, while major urban centers like Khon Kaen, Hat Yai, and Nakhon Ratchasima experience similarly intense UV exposure throughout the year.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is engineered for these conditions:

• Watery, lightweight texture that absorbs quickly without stickiness
• Aloe Vera and Witch Hazel soothe the skin
• Zero white cast – suitable for all skin tones
• Clinically proven cooling effect that instantly reduces skin heat and redness by 86.32%

Who Recommends COSRX in Thailand?

The product has been endorsed by Thailand’s most authoritative skincare voices:

• @ingck – Recognized for ingredient-focused skincare reviews and hands-on testing
• @eb.bahboh – A highly respected medical doctor and creator offering science-backed dermatological expertise

Both have confirmed the product’s efficacy, protection, and suitability for Thai skin after extensive personal use.

Consumers in Thailand can explore COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ and the broader COSRX suncare range through the brand’s official stores on TikTok Shop Thailand and Shopee Thailand. Purchasing through official channels helps ensure product authenticity and access to the latest brand information.

Experience the UK’s No. 1 and Europe’s favorite sunscreen choice and explore the full COSRX range at the Official TikTok Shop Thailand and Official Shopee. COSRX is also on TikTok + Shopee.

Frequently Asked Questions (FAQ)

Q1. What does EU CPNP registration mean?

A1. EU CPNP registration means the product has been notified through the European Union’s Cosmetic Products Notification Portal before being placed on the EU market. It is part of the EU’s regulatory framework for cosmetics.

Q2. What proof supports the product’s consumer popularity in Thailand?

A2. As of April 29, 2026, the product holds a 4.9-star rating across Shopee and TikTok Shop Thailand, with more than 16,000 verified reviews.

Q3. Why is COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ suitable for Thailand’s climate?

A3. It delivers uncompromising, heavy-duty UV defense (SPF50 PA++++) to combat Thailand’s intense sun, without sacrificing daily comfort. Even in hot and humid weather, its watery, lightweight texture absorbs quickly, feels breathable on the skin, and leaves absolutely no white cast.

Q4. Does this sunscreen leave a white cast?

A4. No. COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is designed to deliver an invisible finish without leaving a noticeable white cast on skin.

Q5. Is this product registered in Thailand?

A5. Yes. Thai FDA Registration No. 10-2-6700013181.

Q6. Where can consumers buy authentic COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ in Thailand?

A6. Authentic products are available through COSRX’s official stores on Shopee Thailand and TikTok Shop Thailand.

About COSRX

Rooted in science and driven by results, COSRX is a global beauty brand known for its high performance yet affordable formulations that target real skin concerns with minimal ingredients and maximum efficacy. Trusted by skincare lovers worldwide, COSRX delivers visible results through carefully selected actives in concentrated doses. Discover its award-winning lineup at retailers including COSRX.com, Shopee, TikTok Shop, Beautrium, Watsons and EVEANDBOY. Follow @cosrx.thailand on Instagram and @cosrx.th on TikTok for the latest product drops, tips, and trends.

4.9-Star Rating on Shopee and TikTok Shop Thailand | 16,000+ Verified Reviews

Key Highlights

• Ranked #1 in Sunscreen category on Amazon UK (*April 14, 2026)
•  A European favorite, certified under EU CPNP – one of the world’s strictest cosmetic standards
• 4.9-star rating on Shopee and TikTok Shop Thailand from 16,000+ verified reviews (*as of April 29, 2026)
• Lightweight, zero white cast, optimized for Thailand’s hot-humid climate
• Thai FDA Registration No. 10-2-6700013181

BANGKOK, May 4, 2026 /PRNewswire/ — COSRX, a leading Korean beauty brand, announced today that its Ultra-Light Invisible Sunscreen SPF50 PA++++ has secured the No.1 position in the Sunscreen category in the Amazon UK as of April 14, 2026. Beyond its top ranking, the product has generated strong demand as a European favorite, while reinforcing its market leadership in Thailand with a 4.9-star rating on Shopee and TikTok Shop Thailand from over 16,000 verified consumers.

What is CPNP and Why Does It Matter to Thai Consumers?

The Cosmetic Products Notification Portal (CPNP) is the European Union’s mandatory cosmetic product notification system, requiring rigorous safety assessment before market entry. It is widely regarded as one of the world’s strictest cosmetic regulatory frameworks.

Following the recent UV protection issue, Thai consumers have voiced growing skepticism about the actual UV protection efficacy of the sunscreens. COSRX addresses these concerns with a scientifically validated solution that has become a European favorite – conquering a region renowned for the highest global standards in sun protection.

Why is COSRX Sunscreen Ideal for Thailand’s Climate?

According to the Thai Meteorological Department, the average UV Index in Bangkok measures 11+ (Extreme) year-round, while major urban centers like Khon Kaen, Hat Yai, and Nakhon Ratchasima experience similarly intense UV exposure throughout the year.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is engineered for these conditions:

• Watery, lightweight texture that absorbs quickly without stickiness
• Aloe Vera and Witch Hazel soothe the skin
• Zero white cast – suitable for all skin tones
• Clinically proven cooling effect that instantly reduces skin heat and redness by 86.32%

Who Recommends COSRX in Thailand?

The product has been endorsed by Thailand’s most authoritative skincare voices:

• @ingck – Recognized for ingredient-focused skincare reviews and hands-on testing
• @eb.bahboh – A highly respected medical doctor and creator offering science-backed dermatological expertise

Both have confirmed the product’s efficacy, protection, and suitability for Thai skin after extensive personal use.

Consumers in Thailand can explore COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ and the broader COSRX suncare range through the brand’s official stores on TikTok Shop Thailand and Shopee Thailand. Purchasing through official channels helps ensure product authenticity and access to the latest brand information.

Experience the UK’s No. 1 and Europe’s favorite sunscreen choice and explore the full COSRX range at the Official TikTok Shop Thailand and Official Shopee. COSRX is also on TikTok + Shopee.

Frequently Asked Questions (FAQ)

Q1. What does EU CPNP registration mean?

A1. EU CPNP registration means the product has been notified through the European Union’s Cosmetic Products Notification Portal before being placed on the EU market. It is part of the EU’s regulatory framework for cosmetics.

Q2. What proof supports the product’s consumer popularity in Thailand?

A2. As of April 29, 2026, the product holds a 4.9-star rating across Shopee and TikTok Shop Thailand, with more than 16,000 verified reviews.

Q3. Why is COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ suitable for Thailand’s climate?

A3. It delivers uncompromising, heavy-duty UV defense (SPF50 PA++++) to combat Thailand’s intense sun, without sacrificing daily comfort. Even in hot and humid weather, its watery, lightweight texture absorbs quickly, feels breathable on the skin, and leaves absolutely no white cast.

Q4. Does this sunscreen leave a white cast?

A4. No. COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is designed to deliver an invisible finish without leaving a noticeable white cast on skin.

Q5. Is this product registered in Thailand?

A5. Yes. Thai FDA Registration No. 10-2-6700013181.

Q6. Where can consumers buy authentic COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ in Thailand?

A6. Authentic products are available through COSRX’s official stores on Shopee Thailand and TikTok Shop Thailand.

About COSRX

Rooted in science and driven by results, COSRX is a global beauty brand known for its high performance yet affordable formulations that target real skin concerns with minimal ingredients and maximum efficacy. Trusted by skincare lovers worldwide, COSRX delivers visible results through carefully selected actives in concentrated doses. Discover its award-winning lineup at retailers including COSRX.com, Shopee, TikTok Shop, Beautrium, Watsons and EVEANDBOY. Follow @cosrx.thailand on Instagram and @cosrx.th on TikTok for the latest product drops, tips, and trends.

4.9-Star Rating on Shopee and TikTok Shop Thailand | 16,000+ Verified Reviews

Key Highlights

• Ranked #1 in Sunscreen category on Amazon UK (*April 14, 2026)
•  A European favorite, certified under EU CPNP – one of the world’s strictest cosmetic standards
• 4.9-star rating on Shopee and TikTok Shop Thailand from 16,000+ verified reviews (*as of April 29, 2026)
• Lightweight, zero white cast, optimized for Thailand’s hot-humid climate
• Thai FDA Registration No. 10-2-6700013181

BANGKOK, May 4, 2026 /PRNewswire/ — COSRX, a leading Korean beauty brand, announced today that its Ultra-Light Invisible Sunscreen SPF50 PA++++ has secured the No.1 position in the Sunscreen category in the Amazon UK as of April 14, 2026. Beyond its top ranking, the product has generated strong demand as a European favorite, while reinforcing its market leadership in Thailand with a 4.9-star rating on Shopee and TikTok Shop Thailand from over 16,000 verified consumers.

What is CPNP and Why Does It Matter to Thai Consumers?

The Cosmetic Products Notification Portal (CPNP) is the European Union’s mandatory cosmetic product notification system, requiring rigorous safety assessment before market entry. It is widely regarded as one of the world’s strictest cosmetic regulatory frameworks.

Following the recent UV protection issue, Thai consumers have voiced growing skepticism about the actual UV protection efficacy of the sunscreens. COSRX addresses these concerns with a scientifically validated solution that has become a European favorite – conquering a region renowned for the highest global standards in sun protection.

Why is COSRX Sunscreen Ideal for Thailand’s Climate?

According to the Thai Meteorological Department, the average UV Index in Bangkok measures 11+ (Extreme) year-round, while major urban centers like Khon Kaen, Hat Yai, and Nakhon Ratchasima experience similarly intense UV exposure throughout the year.

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is engineered for these conditions:

• Watery, lightweight texture that absorbs quickly without stickiness
• Aloe Vera and Witch Hazel soothe the skin
• Zero white cast – suitable for all skin tones
• Clinically proven cooling effect that instantly reduces skin heat and redness by 86.32%

Who Recommends COSRX in Thailand?

The product has been endorsed by Thailand’s most authoritative skincare voices:

• @ingck – Recognized for ingredient-focused skincare reviews and hands-on testing
• @eb.bahboh – A highly respected medical doctor and creator offering science-backed dermatological expertise

Both have confirmed the product’s efficacy, protection, and suitability for Thai skin after extensive personal use.

Consumers in Thailand can explore COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ and the broader COSRX suncare range through the brand’s official stores on TikTok Shop Thailand and Shopee Thailand. Purchasing through official channels helps ensure product authenticity and access to the latest brand information.

Experience the UK’s No. 1 and Europe’s favorite sunscreen choice and explore the full COSRX range at the Official TikTok Shop Thailand and Official Shopee. COSRX is also on TikTok + Shopee.

Frequently Asked Questions (FAQ)

Q1. What does EU CPNP registration mean?

A1. EU CPNP registration means the product has been notified through the European Union’s Cosmetic Products Notification Portal before being placed on the EU market. It is part of the EU’s regulatory framework for cosmetics.

Q2. What proof supports the product’s consumer popularity in Thailand?

A2. As of April 29, 2026, the product holds a 4.9-star rating across Shopee and TikTok Shop Thailand, with more than 16,000 verified reviews.

Q3. Why is COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ suitable for Thailand’s climate?

A3. It delivers uncompromising, heavy-duty UV defense (SPF50 PA++++) to combat Thailand’s intense sun, without sacrificing daily comfort. Even in hot and humid weather, its watery, lightweight texture absorbs quickly, feels breathable on the skin, and leaves absolutely no white cast.

Q4. Does this sunscreen leave a white cast?

A4. No. COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ is designed to deliver an invisible finish without leaving a noticeable white cast on skin.

Q5. Is this product registered in Thailand?

A5. Yes. Thai FDA Registration No. 10-2-6700013181.

Q6. Where can consumers buy authentic COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++ in Thailand?

A6. Authentic products are available through COSRX’s official stores on Shopee Thailand and TikTok Shop Thailand.

About COSRX

Rooted in science and driven by results, COSRX is a global beauty brand known for its high performance yet affordable formulations that target real skin concerns with minimal ingredients and maximum efficacy. Trusted by skincare lovers worldwide, COSRX delivers visible results through carefully selected actives in concentrated doses. Discover its award-winning lineup at retailers including COSRX.com, Shopee, TikTok Shop, Beautrium, Watsons and EVEANDBOY. Follow @cosrx.thailand on Instagram and @cosrx.th on TikTok for the latest product drops, tips, and trends.

SHENZHEN, China, May 4, 2026 /PRNewswire/ — XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi’s platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism.

PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi’s ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program’s steady clinical advancement.

Leveraging XtalPi’s integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile.

Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine’s deep oncology expertise with XtalPi’s AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space.

Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4.2 billion to $17.6 billion by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1 billion USD, further underscoring the immense clinical value and commercial appetite for this category.

The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi’s AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform’s evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.

Dr. Shuhao Wen, Chairman of XtalPi commented, “The clinical progress of PEP08 and the ongoing collaboration of the second project are testaments to the synergy between our teams, and highlights the reliability of XtalPi’s R&D platform in tackling complex targets. We look forward to further applying this model to deliver high-quality pipeline assets for our partners and generate sustained value for our shareholders.”

“PharmaEngine has been advancing its R&D capabilities, and our collaboration with XtalPi exemplifies our ability to harness innovative technologies to propel next-generation discoveries in precision oncology,” said Dr. Hong-Ren Wang, CEO and President of PharmaEngine. “XtalPi’s R&D platform played a key role in the early-stage discovery of PEP08, providing a robust foundation for its clinical entry. Our collaboration of PEP08 and the second project demonstrates our ongoing efforts to advance cancer treatment development worldwide.

About PharmaEngine, Inc.

PharmaEngine, Inc. (4162.TWO), headquartered in Taipei, began operations in February 2003. PharmaEngine focuses on new drug development by adopting “Virtual Pharmaceutical Company Business Model”. PharmaEngine has one commercial product, ONIVYDE^®, which is currently approved for the treatment of adult patients with metastatic pancreatic adenocarcinoma. In addition, PharmaEngine is advancing PEP07 (CHK1 inhibitor) and PEP08 (MTA-collaborative PRMT5 inhibitor) through Phase I clinical trials. Leveraging its extensive experience in drug development and project management, the Company aims to continue expanding its pipeline. PharmaEngine also pursues international collaborations and out-licensing agreements to accelerate the discovery, development, and commercialization of novel cancer therapies.

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

SHENZHEN, China, May 4, 2026 /PRNewswire/ — XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi’s platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism.

PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi’s ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program’s steady clinical advancement.

Leveraging XtalPi’s integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile.

Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine’s deep oncology expertise with XtalPi’s AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space.

Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4.2 billion to $17.6 billion by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1 billion USD, further underscoring the immense clinical value and commercial appetite for this category.

The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi’s AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform’s evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.

Dr. Shuhao Wen, Chairman of XtalPi commented, “The clinical progress of PEP08 and the ongoing collaboration of the second project are testaments to the synergy between our teams, and highlights the reliability of XtalPi’s R&D platform in tackling complex targets. We look forward to further applying this model to deliver high-quality pipeline assets for our partners and generate sustained value for our shareholders.”

“PharmaEngine has been advancing its R&D capabilities, and our collaboration with XtalPi exemplifies our ability to harness innovative technologies to propel next-generation discoveries in precision oncology,” said Dr. Hong-Ren Wang, CEO and President of PharmaEngine. “XtalPi’s R&D platform played a key role in the early-stage discovery of PEP08, providing a robust foundation for its clinical entry. Our collaboration of PEP08 and the second project demonstrates our ongoing efforts to advance cancer treatment development worldwide.

About PharmaEngine, Inc.

PharmaEngine, Inc. (4162.TWO), headquartered in Taipei, began operations in February 2003. PharmaEngine focuses on new drug development by adopting “Virtual Pharmaceutical Company Business Model”. PharmaEngine has one commercial product, ONIVYDE^®, which is currently approved for the treatment of adult patients with metastatic pancreatic adenocarcinoma. In addition, PharmaEngine is advancing PEP07 (CHK1 inhibitor) and PEP08 (MTA-collaborative PRMT5 inhibitor) through Phase I clinical trials. Leveraging its extensive experience in drug development and project management, the Company aims to continue expanding its pipeline. PharmaEngine also pursues international collaborations and out-licensing agreements to accelerate the discovery, development, and commercialization of novel cancer therapies.

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

SHENZHEN, China, May 4, 2026 /PRNewswire/ — XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi’s platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism.

PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi’s ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program’s steady clinical advancement.

Leveraging XtalPi’s integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile.

Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine’s deep oncology expertise with XtalPi’s AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space.

Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4.2 billion to $17.6 billion by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1 billion USD, further underscoring the immense clinical value and commercial appetite for this category.

The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi’s AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform’s evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.

Dr. Shuhao Wen, Chairman of XtalPi commented, “The clinical progress of PEP08 and the ongoing collaboration of the second project are testaments to the synergy between our teams, and highlights the reliability of XtalPi’s R&D platform in tackling complex targets. We look forward to further applying this model to deliver high-quality pipeline assets for our partners and generate sustained value for our shareholders.”

“PharmaEngine has been advancing its R&D capabilities, and our collaboration with XtalPi exemplifies our ability to harness innovative technologies to propel next-generation discoveries in precision oncology,” said Dr. Hong-Ren Wang, CEO and President of PharmaEngine. “XtalPi’s R&D platform played a key role in the early-stage discovery of PEP08, providing a robust foundation for its clinical entry. Our collaboration of PEP08 and the second project demonstrates our ongoing efforts to advance cancer treatment development worldwide.

About PharmaEngine, Inc.

PharmaEngine, Inc. (4162.TWO), headquartered in Taipei, began operations in February 2003. PharmaEngine focuses on new drug development by adopting “Virtual Pharmaceutical Company Business Model”. PharmaEngine has one commercial product, ONIVYDE^®, which is currently approved for the treatment of adult patients with metastatic pancreatic adenocarcinoma. In addition, PharmaEngine is advancing PEP07 (CHK1 inhibitor) and PEP08 (MTA-collaborative PRMT5 inhibitor) through Phase I clinical trials. Leveraging its extensive experience in drug development and project management, the Company aims to continue expanding its pipeline. PharmaEngine also pursues international collaborations and out-licensing agreements to accelerate the discovery, development, and commercialization of novel cancer therapies.

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

SHENZHEN, China, May 4, 2026 /PRNewswire/ — XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi’s platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism.

PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi’s ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program’s steady clinical advancement.

Leveraging XtalPi’s integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile.

Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine’s deep oncology expertise with XtalPi’s AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space.

Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4.2 billion to $17.6 billion by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1 billion USD, further underscoring the immense clinical value and commercial appetite for this category.

The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi’s AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform’s evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.

Dr. Shuhao Wen, Chairman of XtalPi commented, “The clinical progress of PEP08 and the ongoing collaboration of the second project are testaments to the synergy between our teams, and highlights the reliability of XtalPi’s R&D platform in tackling complex targets. We look forward to further applying this model to deliver high-quality pipeline assets for our partners and generate sustained value for our shareholders.”

“PharmaEngine has been advancing its R&D capabilities, and our collaboration with XtalPi exemplifies our ability to harness innovative technologies to propel next-generation discoveries in precision oncology,” said Dr. Hong-Ren Wang, CEO and President of PharmaEngine. “XtalPi’s R&D platform played a key role in the early-stage discovery of PEP08, providing a robust foundation for its clinical entry. Our collaboration of PEP08 and the second project demonstrates our ongoing efforts to advance cancer treatment development worldwide.

About PharmaEngine, Inc.

PharmaEngine, Inc. (4162.TWO), headquartered in Taipei, began operations in February 2003. PharmaEngine focuses on new drug development by adopting “Virtual Pharmaceutical Company Business Model”. PharmaEngine has one commercial product, ONIVYDE^®, which is currently approved for the treatment of adult patients with metastatic pancreatic adenocarcinoma. In addition, PharmaEngine is advancing PEP07 (CHK1 inhibitor) and PEP08 (MTA-collaborative PRMT5 inhibitor) through Phase I clinical trials. Leveraging its extensive experience in drug development and project management, the Company aims to continue expanding its pipeline. PharmaEngine also pursues international collaborations and out-licensing agreements to accelerate the discovery, development, and commercialization of novel cancer therapies.

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.